Skip to main content

Peer Review reports

From: Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years

Original Submission
3 Jul 2017 Submitted Original manuscript
4 Feb 2018 Author responded Author comments - Jie Ma
2 Oct 2017 Reviewed Reviewer Report - John Hilton
11 Dec 2017 Reviewed Reviewer Report - Monica N. Fornier
Resubmission - Version 2
4 Feb 2018 Submitted Manuscript version 2
21 Apr 2018 Author responded Author comments - Chi Zhang
27 Mar 2018 Reviewed Reviewer Report - John Hilton
Resubmission - Version 3
21 Apr 2018 Submitted Manuscript version 3
2 Nov 2018 Author responded Author comments - Chi Zhang
20 Jul 2018 Reviewed Reviewer Report - Christina Addison
Resubmission - Version 4
2 Nov 2018 Submitted Manuscript version 4
6 Nov 2018 Author responded Author comments - Chi Zhang
Resubmission - Version 5
6 Nov 2018 Submitted Manuscript version 5
Publishing
12 Nov 2018 Editorially accepted
30 Nov 2018 Article published 10.1186/s12891-018-2338-6

You can find further information about peer review here.

Back to article page